I fail to see why not. It may not be used in the early stages (Primary goal), but it will still be used in the later stages (Secondary goal). This has historically been where the spheres were deployed with success. Previously, it was not even backed by a clin trial, now it is. So I do not see that market going away. If any, I see that market grow as it's now backed by hard data.
Obviously it will not be as big as early stage, hence the reweigh.. but SRX historical dosage sell data stands on its own.
Apart from the monetary loss it's also a disappointing day for those with non resectable liver cancer, I am pretty sure a few of them were hopeful of better treatment outcomes at least in the early stages.
- another specialist.
Ann: Preliminary SIRFLOX Study Results, page-52
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SRX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.8¢ |
Change
0.003(1.43%) |
Mkt cap ! $75.34M | |||
| Open | High | Low | Value | Volume |
| 17.8¢ | 17.8¢ | 17.5¢ | $9.047K | 50.98K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 7293686 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.0¢ | 1399496 | 11 |
View Market Depth
| Last trade - 15.01pm 26/07/2024 (20 minute delay) ? |
| SRX (ASX) Chart |